Study of SHR-3821 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study is testing a new drug, SHR-3821, to see if it can help people with advanced colorectal cancer that has stopped responding to previous treatments. The goal is to evaluate how well it works and what the side effects might be, offering a potential new option for patients who have limited alternatives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that is advanced or has spread, and it cannot be removed with surgery.
- You have already tried at least two lines of standard chemotherapy (including oxaliplatin, irinotecan, and fluoropyrimidine-based treatments).
- You are between 18 and 75 years old.
- Your general health is good enough that you can manage most daily activities on your own (ECOG 0-1).
- Your vital organs (like bone marrow, liver, and kidneys) are functioning within acceptable limits, based on blood tests.
- You have not had untreated brain metastases, and any brain lesions are stable or controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This study tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.